OS Therapies Incorporated Common Stock (OSTX)
1.8406
+0.0306 (1.69%)
NYSE · Last Trade: Jun 27th, 12:19 PM EDT
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · April 28, 2025
Via Benzinga · March 20, 2025

The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via Chartmill · February 14, 2025

Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · February 14, 2025

OS Therapies just reported results for the second quarter of 2024.
Via InvestorPlace · August 25, 2024

OS Therapies advances OST-HER2, a HER2-targeted immunotherapy, with plans for FDA submission following promising Phase 2b data in osteosarcoma.
Via Benzinga · February 14, 2025

Via Benzinga · January 31, 2025

Cancer treatments, FDA breakthroughs, and other developments fueled a sharp spike in interest for these biotech players, as investors bet on promising clinical data and strategic moves.
Via Stocktwits · January 21, 2025

OS Therapies shares Phase 2b trial results showing OST-HER2 improves survival rates in rare metastatic osteosarcoma, surpassing historical controls.
Via Benzinga · January 15, 2025

Via Benzinga · October 3, 2024

Transforming Cancer Therapy Stocks to Watch In The Oncology Sector
Via News Direct · September 12, 2024

Transforming Oncology: Stocks to Watch in the Oncology Sector
Via News Direct · September 12, 2024

Via Benzinga · August 19, 2024

Shares of OS Therapies fell on Thursday following a downsized initial public offering by the oncology drug developer in a slow week for the IPO market.
Via Talk Markets · August 4, 2024